Bronchogen: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 11 sources cited
Overview
Bronchogen is a Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu) that specifically targets bronchial and pulmonary epithelial tissue. Developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson, it is designed to normalize respiratory mucosa function, support healthy bronchial epithelial cell turnover, and restore mucociliary clearance that declines with aging or chronic respiratory conditions. It is part of a broader family of short bioregulatory peptides. The published human studies from this group concern older preparations such as Thymalin and Epithalamin; no clinical trial of Bronchogen itself was found.
Mechanism of Action
As a bioregulator peptide, Bronchogen operates through an epigenetic mechanism fundamentally different from receptor-mediated pharmacology. The tetrapeptide Ala-Glu-Asp-Leu binds DNA in test-tube experiments. In cultured human bronchial epithelial cells it changed the expression of genes involved in epithelial differentiation (NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2), mucin production (MUC4, MUC5AC) and surfactant protein A (SFTPA1), and it altered promoter methylation of NKX2-1 and SCGB1A1. The Khavinson bioregulatory theory posits that tissues produce specific short peptides as part of their normal regulatory processes, and these peptide levels decline with aging, stress, or disease. By supplementing with exogenous tissue-specific peptides like Bronchogen, the theory holds that the gene expression profile of the target tissue is shifted back toward a younger, healthier phenotype. This 'epigenetic resetting' is proposed to improve cellular function without pharmacologically overriding normal signaling — a gentle, restorative approach rather than a forceful one.
Bronchogen Benefits: What the Research Shows
- Khavinson Institute studies in cultured human bronchial epithelial cells showed that Bronchogen changed the expression of differentiation genes (NKX2-1, SCGB1A1, FOXA1, FOXA2) and of MUC4, MUC5AC and SFTPA1, most strongly in aged cultures. No published study in patients with chronic respiratory conditions was found.
- Human studies from this research group, including a 6–8 year follow-up of 266 elderly people, used other preparations (Thymalin and Epithalamin); no published human safety data for Bronchogen itself were found.
- Research on short peptides (2–4 amino acids) by the Khavinson group reported tissue-specific effects in cell and tissue culture, with Bronchogen's Ala-Glu-Asp-Leu sequence stimulating differentiation factors in aging human bronchial epithelial cells and the growth of rat lung explants.
- Higher secretory IgA and surfactant protein B in bronchoalveolar lavage fluid, restored ciliated cells and less neutrophilic inflammation in a rat model of COPD (60 days of nitrogen dioxide exposure) after a one-month course of Bronchogen.
- A long-term study in elderly people reported a 2.0–2.4-fold lower incidence of acute respiratory disease, but it tested Thymalin and Epithalamin, not Bronchogen.
Bronchogen Dosage
- Standard dose: 10 mg subcutaneous injection daily, administered in the morning.
- Typical cycle: 10–20 days. The short cycle length reflects the epigenetic mechanism — the goal is to reset gene expression, after which the effects persist without continued dosing.
- Maintenance: Repeat the 10–20 day cycle every 3–6 months, or seasonally (before cold/flu season and before allergy season).
- Can be combined with other bioregulators in a comprehensive protocol — e.g., Bronchogen for lungs + Cardiogen for heart + Crystagen for immunity, each run sequentially or concurrently.
- Oral capsule formulations are available at higher doses. Follow manufacturer dosing instructions.
- No specific food timing requirements. Inject subcutaneously in the abdomen or thigh.
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Bronchogen Side Effects & Safety
Known Side Effects
- Injection site reactions — mild redness or discomfort, uncommon and self-resolving.
- No published human study has reported on adverse events with Bronchogen; the cell-culture and rat studies do not describe any.
- Allergic reactions are theoretically possible; how often they occur with Bronchogen has not been studied.
- The short treatment cycles (10–20 days) inherently limit adverse event exposure.
- Hormonal, CNS and metabolic effects have not been studied in humans.
Safety Profile
Bronchogen has no published human safety study; the evidence is cell-culture and rat work, nearly all from the research group that developed it. The decades of clinical use in Russian gerontology concern other preparations such as Thymalin and Epithalamin. Short peptides (2–4 amino acids) are expected to be rapidly metabolized and weakly immunogenic, but neither has been measured for Bronchogen in people. The 10–20 day treatment cycles further minimize risk. Contraindications are minimal: known hypersensitivity to the peptide or excipients, and pregnancy/breastfeeding (as a precaution). Interactions with pharmaceutical medications and effects on CYP450 metabolism have not been studied. Safety in elderly people has not been established in a published trial of Bronchogen.
What to Expect
Days 1–5: No immediate subjective effects are expected. Bioregulators work through gradual epigenetic modulation, not acute receptor activation. The peptide is beginning to interact with gene regulatory regions in bronchial tissue. Days 6–15: Some users report subtle improvements in breathing ease, reduced mucus production, or improved respiratory comfort. These effects reflect emerging changes in epithelial gene expression. Days 16–20 (end of cycle): The epigenetic 'reset' is establishing. Effects continue to develop and persist after the cycle ends. Weeks 3–12 (post-cycle): Suppliers and users say benefits manifest and persist for 3–6 months after the treatment course. Reports of better respiratory function, fewer respiratory infections, and improved mucus clearance are anecdotal; no published human study of Bronchogen has measured them.
Common Stacks
Crystagen
Crystagen is used for immune support while Bronchogen supports respiratory tissue integrity — a natural combination for respiratory health and immune defense.
Chonluten
Chonluten targets mucosal epithelium in both lungs and GI tract, complementing Bronchogen's bronchial-specific effects for comprehensive mucosal health.
Thymosin Alpha-1
Thymosin Alpha-1 provides potent immune modulation, complementing Bronchogen's respiratory tissue support for enhanced protection against respiratory infections.
Storage & Handling
Store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution with bacteriostatic water or sodium chloride for injection, refrigerate and use within 20 days (matching the cycle length). Unreconstituted powder shelf life: 24 months when stored properly. Oral capsules: store at room temperature in a cool, dry place.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Khavinson VKh, Tendler SM, Vanyushin BF, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014.
- Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, et al. Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology. Bull Exp Biol Med. 2015.
- Titova ON, Kuzubova NA, Lebedeva ES, et al. ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY. Ross Fiziol Zh Im I M Sechenova. 2017.
- Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012.
- Ashapkin VV, Linkova NS, Khavinson VKh, et al. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015.
- Zakutskiĭ AN, Chalisova NI, Ryzhak GA, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Adv Gerontol. 2006.
- Fedoreyeva LI, Kireev II, Khavinson VKh, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011.
- Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, et al. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011.
- Khavinson V, Linkova N, Kozhevnikova E, et al. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. Int J Mol Sci. 2022.
- Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol. 2013.
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003.
Related Peptides
Track Bronchogen in Your Protocol
Log your Bronchogen doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free